enasidenib
Agios Sells Oncology Business to Servier for $1.8B Upfront
A range of drugs from Agios' cancer pipeline will be transferred to Servier, including two commercial drugs Tibsovo and Idhifa.
Bristol Myers' Idhifa Fails to Meet Phase III Survival Endpoint in Refractory AML
The company said it is evaluating the full data from the IDHENTIFY trial and will present the analysis at an upcoming medical conference.
Agios Sells Royalty Rights to AML Drug Idhifa for $255 Million
The funds from this sale of rights to Royalty Pharma will allow Agios to advance IDH inhibitors and other investigational drugs in its pipeline through clinical trials.
The VA decided to bring this testing in house to streamline and standardize the process for doctors and gauge markers that are relevant to the veteran population.